Mitochondrial targets of metformin-Are they physiologically relevant?

0510611 - FGÚ 2020 RIV NL eng J - Článek v odborném periodiku
Pecinová, Alena - Brázdová, Andrea - Drahota, Zdeněk - Houštěk, Josef - Mráček, Tomáš
Mitochondrial targets of metformin-Are they physiologically relevant?
Biofactors. Roč. 45, č. 5 (2019), s. 703-711. ISSN 0951-6433. E-ISSN 1872-8081
Grant CEP: GA ČR(CZ) GA16-12726S; GA MZd(CZ) NV17-28784A
Institucionální podpora: RVO:67985823
Klíčová slova: AMPK * metformin * mitochondria * oxidative phosphorylation
Obor OECD: Biochemistry and molecular biology
Impakt faktor: 4.734, rok: 2019
Způsob publikování: Omezený přístup
https://doi.org/10.1002/biof.1548

Metformin is the most widely prescribed treatment of hyperglycemia and type II diabetes since 1970s. During the last 15 years, its popularity increased due to epidemiological evidence, that metformin administration reduces incidence of cancer. However, despite the ongoing effort of many researchers, the molecular mechanisms underlying antihyperglycemic or antineoplastic action of metformin remain elusive. Most frequently, metformin is associated with modulation of mitochondrial metabolism leading to lowering of blood glucose or activation of antitumorigenic pathways. Here we review the reported effects of metformin on mitochondrial metabolism and their potential relevance as effective molecular targets with beneficial therapeutic outcome.
Trvalý link: http://hdl.handle.net/11104/0301039